Latent-X2 achieves strong lab results with 4 to 24 designs per target for antibodies, representing efficiency gains of many orders of magnitude compared to conventional screening methods.

Latent-X1 focused on macrocyclic peptides and protein mini-binders with strong binding affinities. Latent-X2 advances to antibodies (VHH, scFv) with drug-like developability and demonstrated low ex vivo immunogenicity in initial studies.These profiles emerge without post-generation iteration.

Typical applications include the design of antibodies (VHH, scFv) and macrocyclic peptides for drug development programs. The model is particularly suited for generating drug-like antibody molecules.

Latent Labs actively participates in biosafety and biosecurity discussions with government and regulatory authorities, regarding responsible development and preventing potential misuse of emerging technologies. Latent Labs continuously assesses its technologies and restricts access to its services in compliance with international sanctions lists from the EU and UK.

Latent Labs is innovating on new frontier AI models that capture the fundamentals of biology, with the aim of empowering scientists to make drugs at the push of a button. The Latent Labs Platform is the first step on this journey.

Latent Labs will not use or share your data. Latent Labs retains the right to learn from aggregate, anonymized user patterns in order to improve its services.

All data is kept strictly confidential. The Latent Labs Platform is GDPR compliant.

Users can keep and use the generated protein sequences via a non-exclusive license.

The Latent-X model will be available via API in the future.

The platform is launching with a free tier for all users, with user credits renewing daily.